Clinical trial · Observational
MRI-based Clinico-radiomics Predicting Lymph Node Metastasis Status of Hilar Cholangiocarcinoma
Evaluation of a MRI-based Clinico-radiomics Model in Predicting Lymph Node Metastasis Status of Hilar Cholangiocarcinoma Patients: a Prospective Diagnostic Study
NCT05626127CI-TRIAL-00062316unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective, observational diagnostic study aiming to assess multiparametric MRI-based clinico-radiomics for identifying lymph node metastasis status in hilar cholangiocarcinoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hilar Cholangiocarcinoma | Hilar Cholangiocarcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No interventions | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Sun Yat-Sen Memorial Hospital of Sun Yat-sen University
- description
- The cohort of Sun Yat-Sen Memorial Hospital of Sun Yat-sen University is the validation cohort.
- interventionNames
- Other: No interventions
Primary outcomes (1)
- measure
- Lymph node metastasis status
- timeFrame
- Baseline
- description
- The value of multiparametric MRI-based clinico-radiomics in predicting lymph node metastasis.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. The patient must sign an informed consent form; 2. Age 18-75 years old, both male and female; 3. ECOG performance status score (PS score) 0-2; 4. Hilar cholangiocarcinoma with resectable tumor lesions; 5. Complete the upper abdomen MRI examination before treatment; Exclusion Criteria: 1. Accompanied with other primary malignant tumors; 2. Patients who have neoadjuvant chemotherapy or other tumor-targeted therapies; 3. Incomplete imaging or medical history data.
References
Publications (0)
Data not yet available
No reference posted for this study.